Formoterol dry-powder inhalation - Novartis

Drug Profile

Formoterol dry-powder inhalation - Novartis

Alternative Names: Eformoterol dry-powder inhalation - Novartis; Foradil Aerolizer; Foradile Aerolizer; Formoterol fumarate dry-powder inhalation - Novartis

Latest Information Update: 28 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 28 May 2003 A pharmacoeconomic study has been added to the Respiratory Tract Disorders therapeutic trials section
  • 18 Mar 2003 Data presented at the 60th Anniversary Meeting of the American Academy of Allergy and Asthma and Immunology (AAAAI-2003) have been added to the Asthma therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top